FOLD 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
FOLD 近期報酬表現
0.74%
Amicus therapeutics, inc
4.57%
同產業平均
0.12%
S&P500
與 FOLD 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
NMRA | Neumora therapeutics inc | - | 2 分 | 2 分 | 2 分 | 1 分 | |
RCKT | Rocket pharmaceuticals inc | 2 分 | 1 分 | 2 分 | 2 分 | 1 分 | |
INSM | Insmed inc | 4 分 | 2 分 | 4 分 | 3 分 | 1 分 | |
DNLI | Denali therapeutics inc | 4 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
TWST | Twist bioscience corp | 3 分 | 4 分 | 4 分 | 2 分 | 1 分 |
- NMRA Neumora therapeutics inc價值 -趨勢 2 分波段 2 分籌碼 2 分股利 1 分查看更多
FOLD 公司資訊
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.